Ancora Advisors’s AEON Biopharma AEON Stock Holding History

Ancora Advisors’s Portfolio AEON Stock Details AEON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-81	Closed	-$41.1K	–	1777
2023 Q2	$41.1K	Buy	+81	New	+$56.9K	﹤0.01%	955
2023 Q1	–	Sell	-233	Closed	-$169K	–	1953
2022 Q4	$169K	Hold	233	–	–	﹤0.01%	708
2022 Q3	$165K	Hold	233	–	–	0.01%	782
2022 Q2	$164K	Hold	233	–	–	﹤0.01%	815
2022 Q1	$164K	Hold	233	–	–	﹤0.01%	855
2021 Q4	$163K	Hold	233	–	–	﹤0.01%	870
2021 Q3	$164K	Hold	233	–	–	﹤0.01%	839
2021 Q2	$161K	Buy	+233	New	+$163K	﹤0.01%	797

Other funds holding AEON

ACM

Atalaya Capital Management New York $45M AUM 3.02% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FAM

Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ancora Advisors's AEON Position: Q3 2023 in Review

Ancora Advisors sold out of AEON Biopharma (AEON) in Q3 2023, closing a stake of 81 shares — an estimated $41.1K sold.

Ancora Advisors first reported a position in AEON in Q2 2021 and held it in 8 quarters. The position peaked at $169K in Q4 2022. 15 funds tracked by Wall St. Rank hold AEON as of Q3 2023.

Ancora Advisors reported no remaining AEON Biopharma position as of Q3 2023 after selling out during the quarter.
Ancora Advisors sold 81 AEON Biopharma shares in Q3 2023, an estimated $41.1K.
Ancora Advisors first reported a position in AEON Biopharma in Q2 2021 and held it in 8 quarters.
Ancora Advisors's AEON Biopharma position peaked at $169K in Q4 2022.
15 funds tracked by Wall St. Rank held AEON Biopharma as of Q3 2023.

Based on Ancora Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.